BridgeBio Pharma
BBIO
199 hedge funds and large institutions have $8.69B invested in BridgeBio Pharma in 2021 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 91 increasing their positions, 38 reducing their positions, and 23 closing their positions.
170% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 23
139% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 38
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
24% more funds holding
Funds holding: 161 → 199 (+38)
1% more capital invested
Capital invested by funds: $8.61B → $8.69B (+$79.4M)
3.97% less ownership
Funds ownership: 98.68% → 94.71% (-4%)
53% less call options, than puts
Call options by funds: $20.8M | Put options by funds: $44.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$190M |
| 2 |
BlackRock
New York
|
+$167M |
| 3 |
ACM
Aisling Capital Management
New York
|
+$136M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$93.4M |
| 5 |
Janus Henderson Group
London,
|
+$71.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$226M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$8.9M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$8.77M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$8.46M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$8.24M |
BBIO Hedge Fund Activity: Q1 2021 in Review
199 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q1 2021, worth a combined $8.69B — up 0.92% from $8.61B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new BBIO positions and 23 closed out — a net gain of 39 holders — while 91 added to existing stakes and 38 trimmed.
The largest buyer was Vanguard Group, adding an estimated $190M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $226M.
- 199 institutional investors held BridgeBio Pharma (BBIO) as of Q1 2021, up from 161 in Q4 2020.
- Funds reported $8.69B of BridgeBio Pharma stock for Q1 2021, up 0.92% quarter-over-quarter.
- 62 funds opened new BridgeBio Pharma positions in Q1 2021 and 23 closed out, a net change of +39 holders.
- The largest BridgeBio Pharma buyer in Q1 2021 was Vanguard Group, an estimated $190M added.
- The largest BridgeBio Pharma seller in Q1 2021 was Kohlberg Kravis Roberts & Co, an estimated $226M sold.
Based on aggregated 13F filings for Q1 2021.